2-甲基-2-丙基[(乙氧羰基)氧基]氨基甲酸酯 | 27868-41-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 中文名称: 2-甲基-2-丙基[(乙氧羰基)氧基]氨基甲酸酯
• 英文名称: N-tert-Butyloxycarbonyl-O-aethoxycarbonyl-hydroxylamin
• 英文别名: Ethyl [(2-methylpropan-2-yl)oxycarbonylamino] carbonate；ethyl [(2-methylpropan-2-yl)oxycarbonylamino] carbonate
• CAS: 27868-41-3
• 化学式: C₈H₁₅NO₅
• 分子量: 205.211
• InChiKey: BYCRGVLKOPGSBM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  73.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-甲基-2-丙基[(乙氧羰基)氧基]氨基甲酸酯 在 盐酸 作用下， 生成 O-Aethoxycarbonyl-hydroxylamin
  参考文献：
  名称：

  关于进一步的 N-未取代的 O-酰基-羟胺 41. 关于羟胺衍生物的交流

  摘要：

  通过 O-酰化乙酰羟肟酯的水解和通过 HCl 裂解，O-酰化叔。丁基-N-羟基氨基甲酸酯可用于制备其他O-酰基-羟胺，包括具有烷氧基羰基和单和二取代氨基甲酰基的那些。

  DOI：

  10.1002/ardp.19703030405
• 作为产物：
  描述：

  N-羟基氨基甲酸叔丁酯 、 氯甲酸乙酯 在 sodium hydroxide 作用下， 生成 2-甲基-2-丙基[(乙氧羰基)氧基]氨基甲酸酯
  参考文献：
  名称：

  关于进一步的 N-未取代的 O-酰基-羟胺 41. 关于羟胺衍生物的交流

  摘要：

  通过 O-酰化乙酰羟肟酯的水解和通过 HCl 裂解，O-酰化叔。丁基-N-羟基氨基甲酸酯可用于制备其他O-酰基-羟胺，包括具有烷氧基羰基和单和二取代氨基甲酰基的那些。

  DOI：

  10.1002/ardp.19703030405

文献信息

• SPECIFIC SYNTHETIC CHIMERIC XENONUCLEIC ACID GUIDE RNA; s(XNA-gRNA) FOR ENHANCING CRISPR MEDIATED GENOME EDITING EFFICIENCY
  申请人：Powell Michael J

  公开号：US20190330621A1

  公开（公告）日：2019-10-31

  The invention provides xenonucleic acids and synthetic chimeric xenonucleic acid guide RNA; s(XNA-gRNA) for enhancing crispr mediated genome editing efficiency. The invention also provides methods and compositions for inducing CRISPR/Cas-based gene editing/regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using single guide RNAs (sgRNAs) that have been chemically modified with xeno nucleic acids which enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a sgRNA that has been chemically modified with xeno nucleic acids to correct a mutation in a target gene associated with the genetic disease.

  该发明提供了xenonucleic acids和合成嵌合xenonucleic acid guide RNA；s(XNA-gRNA)，用于增强criSPr介导的基因组编辑效率。该发明还提供了诱导CRISPR/Cas基因编辑/调控（例如基因组编辑或基因表达）靶向核酸（例如靶向DNA或靶向RNA）在细胞中的方法和组合物。这些方法包括使用已经经过化学修饰的xeno核酸的单导RNA（sgRNAs），这些核酸增强了原代细胞中靶向核酸的基因调控，用于体外治疗或用于体内治疗中的受体细胞。此外，本文提供了通过向受体注射已经经过化学修饰的xeno核酸的足够数量的sgRNA来预防或治疗受体的遗传疾病的方法，以纠正与该遗传疾病相关的靶基因的突变。
• XENONUCLEIC ACID-MEDIATED MULTIPLEX QPCR CLAMPING TECHNOLOGY FOR LUNG CANCER MUTATION DETECTION
  申请人：Sha Michael Y

  公开号：US20220025453A1

  公开（公告）日：2022-01-27

  The invention provides a multiplex method for enriching a plurality of target polynucleotide sequences containing genetic mutations associated with lung cancer comprising: (a) providing a biological sample; (b) isolating DNA from said sample; said DNA including said plurality of target polynucleotide sequences containing genetic mutations; (c) providing a plurality of primer probes targeted to said target polynucleotide sequences said primer probes allowing formation of a PCR product; (d) providing a plurality of target specific xenonucleic acid clamps oligomer probes specific for wildtype polynucleotide sequences; so that during the qPCR process only mutant templates are amplified: (e) admixing the plurality of primer probes and the plurality of xenonucleic clamping probes with the target nucleic acid sample; (f) performing a PCR amplification process in reaction solution under hybridization conditions thereby generating multiple amplicons; and (g) detecting said amplicons and wherein said xenonucleic acid clamps have aza-aza, thio-aza and oxy-aza chemical functionality.
• NOVEL METHOD OF COMBINED MOLECULAR CLAMPING AND ALLELE SPECIFIC qPCR TECHNOLOGY FOR KRAS G12C MUTATION DETECTION
  申请人：Sun Qing

  公开号：US20220025437A1

  公开（公告）日：2022-01-27

  The invention provides a method for detecting KRAS mutations at one or more of codons, said method comprising the steps of: (a) extracting DNA from a biological sample; (b) assaying the DNA via PCR for KRAS mutations at one or more of codons with at least one set of oligonucleotides, wherein the at least one set of oligonucleotides comprises an allele specific forward primer, a reverse primer, a probe and a xenonucleic acid clamp to block amplification of wild type DNA. The xenonucleic acid clamps have aza-aza, thio-aza and oxy-aza chemical functionality.